share_log

啓明醫療-B：所得款項用途檢討的主要發現及繼續暫停買賣

VENUS MEDTECH-B: KEY FINDINGS OF THE USE OF PROCEEDS REVIEW AND CONTINUED SUSPENSION OF TRADING

HKEX ·  Sep 2, 2024 20:34

Summary by Futu AI

啟明醫療-B（VENUS MEDTECH-B）於2024年9月2日發布公告，披露了其所得款項用途檢討的主要發現，並宣布股份將繼續暫停買賣。該檢討由特別委員會委託德勤諮詢（香港）有限公司進行，範圍涵蓋2019年12月1日至2023年12月31日間的股本集資所得款項。檢討發現，約人民幣1,091,783,000元的資金被用於未經授權的交易，且未在過往報告中準確披露。此外，檢討期間發現多項交易缺乏足夠文件記錄，並指出過往財務記錄備存不完整。特別委員會建議加強財務管理政策的監督與執行，並已採取補救行動改善內部控制。公司股份自2023年11月23日起已暫停買賣，並將待達成復牌指引後繼續暫停。
啟明醫療-B（VENUS MEDTECH-B）於2024年9月2日發布公告，披露了其所得款項用途檢討的主要發現，並宣布股份將繼續暫停買賣。該檢討由特別委員會委託德勤諮詢（香港）有限公司進行，範圍涵蓋2019年12月1日至2023年12月31日間的股本集資所得款項。檢討發現，約人民幣1,091,783,000元的資金被用於未經授權的交易，且未在過往報告中準確披露。此外，檢討期間發現多項交易缺乏足夠文件記錄，並指出過往財務記錄備存不完整。特別委員會建議加強財務管理政策的監督與執行，並已採取補救行動改善內部控制。公司股份自2023年11月23日起已暫停買賣，並將待達成復牌指引後繼續暫停。
Venus Medtech-B (VENUS MEDTECH-B) announced on September 2, 2024, disclosing the main findings of the review of the use of funds and announcing that the trading of shares will continue to be suspended. The review was commissioned by the special committee and conducted by Deloitte Consulting (Hong Kong) Limited, covering the capital raising funds from December 1, 2019, to December 31, 2023. The review found that approximately 1,091,783,000 yuan was used for unauthorized transactions and was not accurately disclosed in previous reports. In addition, during the review period, it was found that multiple transactions lacked sufficient document records, and it was pointed out that the past financial records were incomplete. The special committee recommended strengthening the supervision and execution of financial management policies and has taken remedial actions to improve internal controls. The trading of the company's shares has been suspended since November 23, 2023, and will continue to be suspended pending the fulfillment of the resumption guidance.
Venus Medtech-B (VENUS MEDTECH-B) announced on September 2, 2024, disclosing the main findings of the review of the use of funds and announcing that the trading of shares will continue to be suspended. The review was commissioned by the special committee and conducted by Deloitte Consulting (Hong Kong) Limited, covering the capital raising funds from December 1, 2019, to December 31, 2023. The review found that approximately 1,091,783,000 yuan was used for unauthorized transactions and was not accurately disclosed in previous reports. In addition, during the review period, it was found that multiple transactions lacked sufficient document records, and it was pointed out that the past financial records were incomplete. The special committee recommended strengthening the supervision and execution of financial management policies and has taken remedial actions to improve internal controls. The trading of the company's shares has been suspended since November 23, 2023, and will continue to be suspended pending the fulfillment of the resumption guidance.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated